Difference between revisions of "Envafolimab (Enweida)"
Jump to navigation
Jump to search
m |
m |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: PD-L1 antibody. | Class/mechanism: PD-L1 antibody. | ||
| − | <br>Route: | + | <br>Route: SC |
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 11: | Line 10: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[MSI-H or dMMR|MSI-H or dMMR solid tumors (tissue-agnostic)]] | + | *[[Colorectal cancer, MSI-H or dMMR|dMMR colorectal cancer]] |
| + | *[[Malignant solid neoplasm, MSI-H or dMMR|MSI-H or dMMR solid tumors (tissue-agnostic)]] | ||
==History of changes in NMPA indication== | ==History of changes in NMPA indication== | ||
| − | *2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors | + | *2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced [[:Category:Malignant solid neoplasm|solid tumors]] who have experienced disease progression following prior treatment and have no satisfactory alternative treatment options. |
| + | *2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced [[colorectal cancer]] who have experienced disease progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' KN 035 | + | *'''Code name:''' KN-035 |
| + | *'''Brand name:''' Enweida | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| − | [[Category: | + | [[Category:Subcutaneous medications]] |
[[Category:Anti-PD-L1 antibodies]] | [[Category:Anti-PD-L1 antibodies]] | ||
| − | [[Category:MSI-H or dMMR medications]] | + | [[Category:Colorectal cancer medications]] |
| + | [[Category:Malignant solid neoplasm, MSI-H or dMMR medications]] | ||
[[Category:NMPA approved drugs]] | [[Category:NMPA approved drugs]] | ||
Latest revision as of 22:14, 11 January 2024
General information
Class/mechanism: PD-L1 antibody.
Route: SC
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Toxicity management
Diseases for which it is used
History of changes in NMPA indication
- 2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors who have experienced disease progression following prior treatment and have no satisfactory alternative treatment options.
- 2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced colorectal cancer who have experienced disease progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Also known as
- Code name: KN-035
- Brand name: Enweida